Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.32 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462118 | 0.86 | — | — | |
| SCHEMBL3265929 | 0.84 | CA1 (0.38) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL483350 | 0.81 | POLB (0.41) | MEN1POLBKMT2ACA1CA2 | |
| Phosphoric Acid SCHEMBL900121 | 0.80 | POLB (0.38) | MEN1POLBKMT2ACA1CA2 | |
| Sulfuric Acid SCHEMBL1083058 | 0.80 | POLB (0.38) | MEN1POLBKMT2ACA1CA2 | |
| Acetic Acid SCHEMBL4415814 | 0.78 | MEN1 (0.41) | MEN1POLBKMT2ACA1CA2 | |
| Sulfuric Acid SCHEMBL3263770 | 0.78 | MEN1 (0.36) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL7897965 | 0.77 | CA1 (0.34) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL6897699 | 0.72 | — | — | |
| SCHEMBL11374431 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133745-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-10758549-B2 | Compositions of obeticholic acid and methods of use | INTERCEPT PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10751349-B2 | Compositions of obeticholic acid and methods of use | INTERCEPT PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200171053-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-10646499-B2 | Compositions of obeticholic acid and methods of use | INTERCEPT PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200054650-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20200046736-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200046735-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20190255071-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190076446-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-10052337-B2 | Compositions of obeticholic acid and methods of use | INTERCEPT PHARMACEUTICALS, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20170035784-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | INTERCEPT PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-1129686-B1 | Cleansing agents | SHISEIDO CO LTD (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-6548463-B2 | Surfactants and polyoxyalkylene dicarboxylic acid esters; removes makeup with excellent lathering, and provides a refreshing after-shampoo feeling | SHISEIDO COMPANY, LTD. (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20010021691-A1 | Cleansing agents | SHISEIDO COMPANY, LTD. | 2001-09-13 | — | — | US | disclosed |
| EP-1129686-A1 | Cleansing agents | SHISEIDO COMPANY LIMITED (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6194108-B1 | FORMING AN IMAGE BY AN ELECTROCHEMICAL DEPOSITION OR BUILD-UP PHENOMENON, USING A DISPERSION IN WHICH COLORING MATERIAL FINE PARTICLES ARE DISPERSED IN AQUEOUS LIQUID | FUJI XEROX CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646499-B2 | Compositions of obeticholic acid and methods of use | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-10751349-B2 | Compositions of obeticholic acid and methods of use | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20190076446-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20170035784-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20220133745-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20190255071-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20200046736-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20200054650-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20200046735-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20200171053-A1 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-10758549-B2 | Compositions of obeticholic acid and methods of use | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-10052337-B2 | Compositions of obeticholic acid and methods of use | OTC, ERGIC1, CEL | CA1 915/4885CA2 1124/4885MEN1 1370/4885 |
| US-20010021691-A1 | Cleansing agents | PYM1, SMURF1, SMURF2 | CA1 3380/4885CA2 2576/4885MEN1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.